NYSE · NVS
Novartis AG financials
$145.71−0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '16 Jun 30 | Q1 '16 Mar 31 | Q4 '15 Dec 31 | Q3 '15 Sep 30 | Q2 '15 Jun 30 | Q1 '15 Mar 31 | Q4 '14 Dec 31 | Q3 '14 Sep 30 | Q2 '14 Jun 30 | Q1 '14 Mar 31 | Q4 '13 Dec 31 | Q3 '13 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.68B | $11.81B | $12.80B | $12.48B | $12.90B | $12.20B | $13.35B | $13.30B | $13.95B | $13.03B | $13.63B | $12.91B |
| Gross profit | $8.23B | $7.60B | $8.26B | $8.10B | $8.41B | $8.22B | $8.94B | $8.88B | $9.57B | $8.90B | $9.20B | $8.78B |
| Gross margin | 64.9% | 64.3% | 64.5% | 64.9% | 65.2% | 67.4% | 66.9% | 66.8% | 68.6% | 68.3% | 67.5% | 68.0% |
| Operating income | $1.85B | $2.25B | $1.90B | $2.44B | $1.92B | $2.87B | $2.44B | $3.15B | $3.57B | $3.05B | $2.57B | $2.89B |
| Net income | $1.80B | $2.01B | $1.05B | $1.89B | $1.84B | $13.01B | $1.49B | $3.22B | $2.56B | $2.94B | $2.03B | $2.23B |
| Net margin | 14.2% | 17.0% | 8.2% | 15.1% | 14.2% | 106.6% | 11.2% | 24.2% | 18.3% | 22.6% | 14.9% | 17.3% |
| Diluted EPS | $0.75 | $0.84 | $0.45 | $0.77 | $0.75 | $5.32 | $0.61 | $1.31 | $1.03 | $1.19 | $0.82 | $0.90 |
| EBITDA | $3.32B | $3.62B | $1.90B | $3.80B | $3.43B | $4.16B | $2.44B | $4.32B | $4.74B | $4.17B | $2.57B | $3.99B |
| Operating cash flow | $3.11B | $1.54B | $4.16B | $3.13B | $2.91B | $1.70B | $5.21B | $4.01B | $3.34B | $1.34B | $4.45B | $4.38B |
| Free cash flow | $2.66B | $1.16B | $3.32B | $2.55B | $2.34B | $1.24B | $4.32B | $3.34B | $2.70B | $859.0M | $3.36B | $3.62B |
| Diluted shares | 2,401.0M | 2,398.0M | 2,439.4M | 2,438.0M | 2,451.0M | 2,446.0M | 2,472.2M | 2,460.0M | 2,471.0M | 2,479.0M | 2,479.0M | 2,480.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.44B | $11.46B | $13.39B | $7.52B | $12.41B | $9.66B |
| Short-term investments | $0.00 | $0.00 | $1.03B | $11.41B | $15.92B | $1.91B |
| Total debt | $5.60B | $8.23B | $18.44B | $26.18B | $29.20B | $36.04B |
| Total assets | $110.95B | $102.25B | $99.94B | $117.45B | $131.79B | $127.78B |
| Total liabilities | $64.40B | $58.12B | $53.20B | $58.03B | $63.97B | $71.11B |
| Shareholders' equity | $46.55B | $44.13B | $46.75B | $59.42B | $67.82B | $56.67B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology